openPR Logo
Press release

Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market is projected to reach USD 6.54 billion by 2034

12-10-2025 11:33 AM CET | Health & Medicine

Press release from: Exactitude Consultancy

Systemic Sclerosis-Associated Interstitial Lung Disease

Systemic Sclerosis-Associated Interstitial Lung Disease

The global Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market was valued at USD 3.12 billion in 2024 and is projected to reach USD 6.54 billion by 2034, growing at a CAGR of 7.8% during the forecast period (2025-2034). Growth is driven by rising awareness of systemic sclerosis complications, increasing ILD diagnosis rates, expanding access to antifibrotic therapies, and strong adoption of immunomodulatory treatments that slow disease progression.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71355

SSc-ILD is the leading cause of morbidity and mortality in systemic sclerosis patients. It involves progressive fibrosis and inflammation of the lungs, reducing lung capacity, impairing gas exchange, and increasing the risk of respiratory failure. Early intervention and multidisciplinary care have dramatically improved survival, and the availability of disease-modifying therapeutics has transformed the treatment landscape.

Key Market Highlights
• 2024 Market Size: USD 3.12 billion
• 2034 Forecast: USD 6.54 billion
• CAGR (2025-2034): 7.8%
• Primary Therapy Classes: Antifibrotics & immunomodulators
• Fastest-Growing Segment: Biologics targeting immune and fibrotic pathways

Epidemiology & Patient Insights
1. Prevalence of Systemic Sclerosis
• Systemic sclerosis affects 50-300 per million people globally.
• Up to 80% develop some degree of ILD.
• Approximately 35-45% develop clinically significant SSc-ILD requiring long-term therapy.
2. High-Risk Groups
• Diffuse cutaneous systemic sclerosis
• Patients with anti-Scl-70 (topoisomerase I) antibodies
• Individuals with early, rapidly progressive disease
3. Disease Burden
SSc-ILD leads to:
• Chronic dyspnea
• Persistent cough
• Progressive decline in forced vital capacity (FVC)
• Increased hospitalization and mortality
Early diagnosis via HRCT and PFTs is key to slowing progression.

Market Growth Drivers
1. Increasing Adoption of Antifibrotic Therapies
Drugs that reduce lung fibrosis progression are now widely used in systemic sclerosis patients.
2. Advances in Immunomodulatory Treatments
Immunosuppressants such as MMF and cyclophosphamide remain foundational, while biologics and targeted therapies are growing rapidly.
3. Improved Screening & Diagnosis
Early use of:
• High-resolution CT (HRCT)
• Pulmonary function tests (PFTs)
• Autoantibody panels
has increased treatment initiation at earlier stages.
4. Rising Awareness of Connective Tissue Disease-ILD
Rheumatologists and pulmonologists increasingly collaborate for early disease management.
5. Strong Pipeline of Novel Therapies
Several antifibrotic, anti-inflammatory, and immune pathway modulators are in late-stage clinical trials.

Market Restraints
• High treatment costs for biologics and antifibrotics
• Slow disease recognition in early stages
• Limited specialist availability in developing regions
• Long-term safety concerns with chronic immunosuppressive therapy

Market Opportunities
1. Next-Generation Antifibrotic Drugs
Better tolerability and enhanced FVC preservation are key innovation areas.
2. Precision Immunology
Cytokine profiling and genomic markers will support personalized therapy decisions.
3. Combination Therapy Approaches
Emerging data support using antifibrotic + immunomodulator combinations.
4. AI-Enabled Early Detection
AI-enhanced CT scan interpretation can detect ILD earlier than conventional methods.
5. Telehealth & Remote Monitoring
SSc-ILD patients benefit from remote lung function monitoring and symptom tracking.

Segmentation Overview
By Treatment Type
• Antifibrotics
• Immunosuppressants
• Biologics
• Corticosteroids
• Oxygen therapy
• Supportive care & rehabilitation

By Disease Severity
• Mild
• Moderate
• Severe / progressive

By Route of Administration
• Oral
• Injectable
• Infusion-based biologics

By End User
• Hospitals
• Pulmonary care centers
• Rheumatology clinics
• Specialty pharmacies

Explore Full Report here: https://exactitudeconsultancy.com/reports/71355/systemic-sclerosis-associated-interstitial-lung-disease-market

Regional Insights
North America - Largest Market
Strong adoption of antifibrotics, advanced rheumatology-pulmonology networks, and high disease awareness.
Europe - Structured ILD Care Pathways
Standardized guidelines and robust clinical research in systemic sclerosis and ILD.
Asia Pacific - Fastest Growing Market
Rising autoimmune disease prevalence, improved ILD screening, and expanding healthcare access.
Latin America - Growing Focus on ILD Management
Improved specialist availability and better access to immunosuppressant therapy.
Middle East & Africa - Developing
Gradual improvements in autoimmune disease diagnostics and pulmonary care.

Competitive Landscape
Major companies active in the SSc-ILD treatment market include:
• Boehringer Ingelheim
• Roche
• Novartis
• Bristol Myers Squibb
• Merck
• GSK
• Pfizer
• Sanofi
• UCB Pharma
• Bayer
Focus areas: antifibrotics, cytokine-blocking biologics, immune modulators, and precision fibrosis therapies.

Recent Market Developments
• Expansion of antifibrotic therapies into SSc-ILD and mixed ILD populations
• Clinical progress in biologics targeting immune pathways involved in fibrosis
• Increased adoption of combination immunosuppression + antifibrotic regimens
• New diagnostic algorithms using HRCT + AI tools
• Enhanced integration of pulmonary rehabilitation into SSc-ILD care

Future Outlook (2025-2034)
The SSc-ILD Market will expand rapidly as:
• Antifibrotics gain broader acceptance
• Biologics reshape progressive ILD treatment
• AI-driven early detection becomes standard
• Combination therapy improves patient outcomes
• Global access to autoimmune disease care expands
By 2034, the market is projected to reach USD 6.54 billion, supported by innovation in fibrosis management and rising global disease awareness.

This report is also available in the following languages : Japanese (全身性硬化症関連間質性肺疾患市場), Korean (전신성 경화증 관련 간질성 폐질환 시장), Chinese (系统性硬化症相关间质性肺病市场), French (Marché des maladies pulmonaires interstitielles associées à la sclérose systémique), German (Markt für interstitielle Lungenerkrankungen im Zusammenhang mit systemischer Sklerose), and Italian (Mercato della malattia polmonare interstiziale associata alla sclerosi sistemica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71355

Our More Reports:

Connective Tissue Disease associated with Interstitial Lung Disease Market
https://exactitudeconsultancy.com/reports/71473/connective-tissue-disease-associated-with-interstitial-lung-disease-market

Progressive Fibrosing Interstitial Lung Disease Market
https://exactitudeconsultancy.com/reports/71479/progressive-fibrosing-interstitial-lung-disease-market

MAC Lung Disease Market
https://exactitudeconsultancy.com/reports/71506/mac-lung-disease-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market is projected to reach USD 6.54 billion by 2034 here

News-ID: 4309708 • Views:

More Releases from Exactitude Consultancy

Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitation and Infrastructure Projects
Cold Planer Market Sees Consistent Growth Supported by Global Road Rehabilitatio …
The global cold planer market is experiencing steady growth as governments and private contractors increase spending on road rehabilitation, resurfacing, and infrastructure modernization. Cold planers, also known as milling machines, are widely used to remove damaged asphalt and concrete surfaces efficiently, supporting sustainable road construction practices. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68250 Key Market Highlights • Increasing focus on road maintenance and resurfacing projects • Growing demand for efficient and precision milling
Credit Management Software Market Accelerates as Organizations Focus on Risk Mitigation and Cash Flow Optimization
Credit Management Software Market Accelerates as Organizations Focus on Risk Mit …
The global credit management software market is witnessing robust growth as organizations across industries adopt digital solutions to manage credit risk, improve receivables performance, and strengthen financial controls. Credit management software enables businesses to automate credit scoring, monitor customer creditworthiness, and streamline collections processes. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68248 Key Market Highlights • Growing adoption of automated credit risk assessment tools • Increasing focus on working capital and cash flow management • Integration
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Operators Strengthen Network Security
Session Border Controller Market Expands Rapidly as Enterprises and Telecom Oper …
The global session border controller (SBC) market is experiencing strong growth as telecom operators and enterprises increasingly deploy SBC solutions to secure, manage, and optimize real-time IP communications. SBCs play a critical role in protecting voice over IP (VoIP), unified communications (UC), and multimedia sessions from cyber threats while ensuring interoperability and quality of service. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68246 Key Market Highlights • Growing adoption of VoIP and
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Traction Amid Global Decarbonization Efforts
Biofuel Market Including E-Methane and Sustainable Aviation Fuel Gains Strong Tr …
The global biofuel market, encompassing e-methane, sustainable aviation fuel (SAF), and other advanced biofuels, is witnessing robust growth as governments and industries intensify efforts to reduce carbon emissions and transition toward cleaner energy sources. These fuels play a critical role in achieving net-zero targets while enabling decarbonization of hard-to-abate sectors such as aviation, shipping, and heavy transportation. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/68244 Key Market Highlights • Rapid growth of

All 5 Releases


More Releases for ILD

PH-ILD Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveIns …
DelveInsight's "Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pulmonary Hypertension Associated with Interstitial Lung Disease, historical and forecasted epidemiology as well as the Pulmonary Hypertension Associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the PH-ILD market outlook, drug uptake,
PH-ILD Market Set to Grow Substantially Through 2034, DelveInsight Projects
DelveInsight's "Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pulmonary Hypertension Associated with Interstitial Lung Disease, historical and forecasted epidemiology as well as the Pulmonary Hypertension Associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the PH-ILD market outlook, drug uptake,
Connective tissue disease-associated ILD (CTD-ILD) Patient Pool Analysis Market …
Connective tissue disease-associated interstitial lung disease (CTD-ILD) refers to a group of serious lung complications arising from autoimmune conditions such as rheumatoid arthritis, systemic sclerosis, lupus, and dermatomyositis. Characterized by progressive scarring and impaired lung function, CTD-ILD is one of the most severe extra-pulmonary manifestations of connective tissue disorders. Download Full PDF Sample Copy of Market Report @https://exactitudeconsultancy.com/request-sample/71523 As diagnostic techniques improve and awareness among clinicians increases, more CTD-ILD cases are being
Systemic Sclerosis-Associated ILD Market to Grow to USD 8.1 Billion by 2034
Systemic sclerosis (SSc) is a rare, chronic autoimmune disease that causes fibrosis of the skin and internal organs. Among its most serious complications is interstitial lung disease (ILD), which remains a leading cause of mortality in patients. The condition is complex and progressive, creating significant unmet medical needs and healthcare burdens. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71355 In recent years, the SSc-ILD market has gained global attention, with
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Market Massive …
Introduction Systemic sclerosis (scleroderma) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular damage, and immune system dysfunction. Among its most serious complications is systemic sclerosis-associated interstitial lung disease (SSc-ILD), a progressive and potentially fatal condition that significantly reduces quality of life and survival rates. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71331 Historically, treatment relied on immunosuppressants such as cyclophosphamide and mycophenolate mofetil, but
Global CMP Slurry for ILD and STI Market Research Report 2024-2030
Global Leading Market Research Publisher QYResearch announces the release of its lastest report "Global CMP Slurry for ILD and STI Market Report, History and Forecast 2019-2030, Breakdown Data by Manufacturers, Key Regions, Types and Application". Based on historical analysis (2019-2023) and forecast calculations (2024-2030), this report provides a comprehensive analysis of the global CMP Slurry for ILD and STI market, including market size, share, demand, industry development status, and forecasts